Shiva Pharmachem Pre-IPO - High Borrowings Along with Expansion Plans Leading to Liquidity Concerns
Shiva PharmaChem is looking to raise around US$110m in its India IPO. In this note, we talk about the company’s historical performance.
659 Views
Alkyl Amines: Supply Glut in the Domestic Market. Maintain SELL
We expect EBITDA/APAT to grow at a CAGR of 19/21% over FY24-27E and RoE/RoCE to improve from 12.2/15.7% in FY24 to 11.4/14.8% in FY27. Currently,...
526 Views
Alkyl Amines: Testing Times Ahead. Downgrade to SELL
We downgrade Alkyl Amines (AACL) from a REDUCE to a SELL, with a price target of INR 2,100 (WACC 12%, terminal growth 5%)
301 Views
HSIE Results Daily: Dabur, Godrej Properties, Alkyl Amines and More
Dabur: Daburs Q1 performance was inspiring with a beat in revenue, volume and EBITDA. Revenue growth was at 32% YoY (HSIE 22%), 2-year CAGR at 7%....
340 Views
Alkyl Amines (4QFY21): Pricing in positives. Downgrade to SELL
We like Alkyl Amines owing to (1) robust demand from pharma and agrochemical industry that comprise more than 75% of its revenue mix; (2) doubling...
550 Views